Unknown

Dataset Information

0

Structure-based evolution of subtype-selective neurotensin receptor ligands.


ABSTRACT: Subtype-selective agonists of the neurotensin receptor NTS2 represent a promising option for the treatment of neuropathic pain, as NTS2 is involved in the mediation of ?-opioid-independent anti-nociceptive effects. Based on the crystal structure of the subtype NTS1 and previous structure-activity relationships (SARs) indicating a potential role for the sub-pocket around Tyr11 of NT(8-13) in subtype-specific ligand recognition, we have developed new NTS2-selective ligands. Starting from NT(8-13), we replaced the tyrosine unit by ?(2)-amino acids (type 1), by heterocyclic tyrosine bioisosteres (type 2) and peptoid analogues (type 3). We were able to evolve an asymmetric synthesis of a 5-substituted azaindolylalanine and its application as a bioisostere of tyrosine capable of enhancing NTS2 selectivity. The S-configured test compound 2 a, [(S)-3-(pyrazolo[1,5-a]pyridine-5-yl)-propionyl(11)]NT(8-13), exhibits substantial NTS2 affinity (4.8 nm) and has a nearly 30-fold NTS2 selectivity over NTS1. The (R)-epimer 2 b showed lower NTS2 affinity but more than 600-fold selectivity over NTS1.

SUBMITTER: Schaab C 

PROVIDER: S-EPMC4234217 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Structure-based evolution of subtype-selective neurotensin receptor ligands.

Schaab Carolin C   Kling Ralf Christian RC   Einsiedel Jürgen J   Hübner Harald H   Clark Tim T   Seebach Dieter D   Gmeiner Peter P  

ChemistryOpen 20140923 5


Subtype-selective agonists of the neurotensin receptor NTS2 represent a promising option for the treatment of neuropathic pain, as NTS2 is involved in the mediation of μ-opioid-independent anti-nociceptive effects. Based on the crystal structure of the subtype NTS1 and previous structure-activity relationships (SARs) indicating a potential role for the sub-pocket around Tyr11 of NT(8-13) in subtype-specific ligand recognition, we have developed new NTS2-selective ligands. Starting from NT(8-13),  ...[more]

Similar Datasets

| S-EPMC7395530 | biostudies-literature
| S-EPMC7044277 | biostudies-literature
| S-EPMC4022043 | biostudies-literature
| S-EPMC5433701 | biostudies-literature
| S-EPMC4063337 | biostudies-literature
| S-EPMC3926081 | biostudies-literature
| S-EPMC3246544 | biostudies-literature
| S-EPMC4002130 | biostudies-literature
| S-EPMC4186986 | biostudies-literature
| S-EPMC3482300 | biostudies-literature